1800-272-662
Shopping Cart 0
countryflagAU
Login

Microba Life Sciences Ltd

Healthcare AU MAP

0.08AUD
-(-%)

Last update at 2026-03-13T04:09:00Z

Day Range

0.080.08
LowHigh

52 Week Range

0.070.23
LowHigh

Fundamentals

  • Previous Close 0.08
  • Market Cap48.72M
  • Volume89553
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-23.05986M
  • Revenue TTM14.90M
  • Revenue Per Share TTM0.03
  • Gross Profit TTM 6.97M
  • Diluted EPS TTM-0.04

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -15.04607M -19.98979M -12.67457M -11.46120M -7.52375M
Minority interest - - - - -
Net income -14.93947M -19.93849M -12.68021M -11.47043M -7.52375M
Selling general administrative 16.95M 12.18M 9.64M 8.57M 7.86M
Selling and marketing expenses 0.66M 0.79M - 0.54M -
Gross profit 7.44M 5.91M 2.68M 2.37M 2.06M
Reconciled depreciation 4.43M 2.87M 1.64M 1.54M -
Ebit -14.94216M -19.97119M -20.23012M -11.45289M -9.52115M
Ebitda -10.51098M -17.10092M -11.01633M -9.91003M -
Depreciation and amortization 4.43M 2.87M - 1.54M -
Non operating income net other - - - - -
Operating income -24.60858M -26.84291M -12.67765M -11.45289M -7.52376M
Other operating expenses 40.28M 38.93M 2.29M 20.96M 0.93M
Interest expense 0.18M 0.07M 1.19M 0.00831M 0.08M
Tax provision -0.10659M -0.05130M 0.00564M 0.00923M 0.00000M
Interest income 0.58M 1.00M 0.88M 0.05M -
Net interest income 0.41M 0.94M 0.82M -0.00574M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.10659M -0.05130M 0.00564M 0.00923M -
Total revenue 15.67M 12.09M 5.42M 4.69M 3.73M
Total operating expenses 32.05M 32.75M - 18.64M -
Cost of revenue 8.23M 6.18M 2.74M 2.32M 1.67M
Total other income expense net 9.56M 6.85M 6.74M 4.82M -
Discontinued operations - - - - -
Net income from continuing ops -14.93947M -19.93849M -12.68021M -11.47043M -
Net income applicable to common shares -14.93947M -19.93849M -12.68021M -11.47043M -7.52375M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 47.44M 58.04M 46.95M 39.48M 18.49M
Intangible assets 14.54M - 2.85M 0.85M 1.07M
Earning assets - - - - -
Other current assets 0.33M 1.01M 1.14M 0.20M 0.00011M
Total liab 14.94M 16.37M 8.38M 5.94M 3.55M
Total stockholder equity 32.49M 41.22M 38.57M 33.54M 14.94M
Deferred long term liab - - 2.66M 0.64M 0.82M
Other current liab 1.99M 5.28M 2.22M 3.61M 1.64M
Common stock - 102.88M 80.37M 62.88M 33.48M
Capital stock 108.54M - 80.37M 62.88M -
Retained earnings -78.76065M -63.82118M -43.88269M -31.20248M -19.73205M
Other liab - - 0.32M 0.19M 0.13M
Good will 10.02M - - - -
Other assets - 0.00000M 2.66M 0.64M 0.82M
Cash 11.74M 20.89M 18.68M 30.58M 12.98M
Cash and equivalents - - 12.43M 0.20M 0.05M
Total current liabilities 10.17M 12.37M 7.82M 5.26M 3.35M
Current deferred revenue - 2.18M - 2.55M -
Net debt - -19.30805M - -29.25554M -
Short term debt - 1.21M 0.00000M 0.84M 0.00000M
Short long term debt 0.75M - 0.36M 0.36M -
Short long term debt total - 1.58M - 1.33M -
Other stockholder equity - - 2.08M 0.08M 1.19M
Property plant equipment - - 2.58M 2.81M 1.20M
Total current assets 19.00M 32.25M 41.53M 35.82M 16.22M
Long term investments - - - - -
Net tangible assets - - 38.39M 33.33M 14.69M
Short term investments - - - - -
Net receivables 0.46M 8.10M 7.24M 3.42M 1.65M
Long term debt 0.47M - - - 0.00000M
Inventory 1.94M 2.24M 0.64M 0.36M 0.51M
Accounts payable 2.35M 3.70M 2.98M 0.81M 0.35M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 2.16M - 1.85M -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 21.88M - - -
Deferred long term asset charges - - - - -
Non current assets total 28.44M 25.79M 5.43M 3.66M -
Capital lease obligations 2.01M - 0.78M 0.96M -
Long term debt total - - 0.23M 0.48M 0.07M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -2.83358M -13.94918M -2.99880M -1.73235M -
Change to liabilities - - 2.53M 1.14M 0.49M
Total cashflows from investing activities -2.83358M -13.94918M -2.99880M -1.73235M -0.57278M
Net borrowings 0.82M 0.06M -0.55317M -0.12924M -0.35800M
Total cash from financing activities 5.58M 18.39M 16.68M 29.22M 13.84M
Change to operating activities - - -0.05667M 0.23M -0.57456M
Net income -14.93947M -19.93849M -12.68021M -11.47043M -7.52375M
Change in cash -9.14854M -11.15442M 1.46M 17.60M 6.08M
Begin period cash flow 20.89M 32.04M 30.58M 12.98M -
End period cash flow 11.74M 20.89M 32.04M 30.58M 12.98M
Total cash from operating activities -12.01251M -15.56694M -12.39383M -10.44881M -7.18158M
Issuance of capital stock 6.05M 20.36M 17.83M 31.25M -
Depreciation - 2.87M 1.22M 1.15M 0.83M
Other cashflows from investing activities -2.57298M -2.89173M 0.04M 0.14M 0.10M
Dividends paid - - - -0.42535M -
Change to inventory -0.26483M -0.31057M -0.28439M 0.15M -0.17247M
Change to account receivables 3.99M -0.01020M -3.81368M -1.77260M -1.02713M
Sale purchase of stock -0.38466M -1.25734M 17.83M -1.90495M 15.14M
Other cashflows from financing activities -0.89694M -0.76509M -0.59563M 0.09M -0.95131M
Change to netincome - - 0.26M -0.26850M 0.41M
Capital expenditures 2.90M 4.38M 0.55M 1.87M 0.25M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 3.35M 0.99M 3.53M 2.85M 1.16M
Stock based compensation - - - - -
Other non cash items -15.36431M 0.51M - - -
Free cash flow -14.91188M -19.94599M -15.43072M -1.87276M -

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MAP
Microba Life Sciences Ltd		 - -% 0.08 - - 3.27 1.61 2.68 -7.9984
SHL
Sonic Healthcare Ltd		 0.09 0.43% 21.20 19.10 15.48 1.01 1.22 1.52 8.99
IDX
Integral Diagnostics Ltd		 0.01 0.43% 2.32 57.75 15.80 1.12 1.30 1.89 12.08
HLS
Healius Ltd		 - -% 0.59 - 26.25 0.32 0.78 0.96 10.14
ACL
Australian Clinical Labs Ltd		 -0.02 0.97% 2.05 14.79 12.17 0.54 2.75 0.96 3.92

Reports Covered

Stock Research & News

View All

Profile

Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; MetaXplore that provides a range of diagnostics solution under the Co-Biome brand; research testing services; and data-driven therapeutics platform that develops therapies for ulcerative colitis, and inflammatory bowel and autoimmune diseases, as well as microbiome databank. Microba Life Sciences Limited was incorporated in 2017 and is based in Brisbane, Australia.

Microba Life Sciences Ltd

324 Queen Street, Brisbane, QLD, Australia, 4000

Key Executives

Name Title Year Born
Dr. Luke Reid Chief Exec. Officer NA
Prof. Gene Tyson Co-Founder & Non-Exec. Director NA
Mr. James Heath CFO & Company Sec. NA
Prof. Philip Hugenholtz Co-Founder & Chair of Scientific Advisory Board NA
Mr. Yao Liu Chief Technology Officer NA
Prof. Lutz Krause Chief Scientific Officer NA
Mr. Drew Webb Chief Marketing Officer NA
Prof. Trent Munro Sr. VP of Therapeutics NA
Dr. Nicola Angel Head of Laboratory Operations NA
Mr. Bernie Woodcroft Sr. VP of Platform Solutions NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.